Communications
Asymmetric Heterocycle Synthesis
1) methodology must be available for the convenient syn-
thesis of oxadiazolidinones in optically active form,[5] and
2) the heterocycle 3 (intermediates and end products) must be
configurationally stable. Examination of related heterocycles
casts into question the configurational stability, especially
under acidic and alkaline conditions (Scheme 1). In this
1,2,4-Oxadiazolidinones as Configurationally
Stable Chiral Building Blocks**
Tobias Ritter and Erick M. Carreira*
Heterocycles are ubiquitous in drug discovery and develop-
ment by virtue of the fact that they can serve as scaffolds
incorporating multiple points of diversification and thereby
facilitate library synthesis. Nonaromatic heterocycles can
impart added benefits in drug design, because they define out-
of-plane vectors from a central core. One of the more recent
examples of such a scaffold is the antibacterial linezolid, an
optically active oxazolidinone.[1,2] Chiral 1,2,4-oxadiazolidi-
nones 3 [Eq. (1)] constitute a structurally intriguing scaffold,
Scheme 1. Configurational stabiliy of heterocycles related to oxadiazoli-
dinones.
respect, oxazolidinone 4 racemizes upon heating in acetoni-
trile[6] and the cyclic nitrone 5 was found to undergo rapid
racemization during chromatography on silica gel through
putative ring opening to the acyl imminium ion and subse-
quent recyclization.[7] The imidazolidinone scaffold 6 was
reported to undergo degradation to the Schiff base upon
vacuum distillation (1358C, 0.05 torr).[8]
Our recent work in alkynylzinc additions to mannosyl-
and erythrosyl- (Aux1 and Aux2, respectively) derived nitro-
nes[9] led us to explore these substrates[10] in the cycloaddition
reaction for the preparation of oxadiazolidinones. The start-
ing nitrones are conveniently accessed from readily available
starting materials (mannose, hydroxylamine, aldehyde) in
three steps.[11]
Simply mixing a range of commercially available isocya-
nates 1 with mannosyl-derived nitrones 2 in CH2Cl2 led to
smooth cycloaddition at 238C to afford oxadiazolidinones 7 in
69–87% yield [Eq. (2), Table 1]. The diastereoselectivity of
the cycloaddition ranges from 4:1 to 12:1 for the products
isolated directly upon evaporation of the solvent. We were
pleased to observe that simple trituration of the products with
methanol generally furnished the desired substituted 1,2,4-
oxadiazolidinones in up to > 99:1 d.r. in analytically pure
form. Electron-deficient and -rich aromatic and heteroaro-
matic nitrones, alkenylnitrones, as well as alkylnitrones
participate in this cycloaddition, with the C-alkylnitrones
most and the electron-deficient aromatic least reactive.
Electron-deficient isocyanates react more readily than those
substituted with electron-releasing groups, consistent with
frontier orbital control. Reactions of substrates that are less
reactive can be carried out successfully in refluxing acetoni-
trile.
which bear structural similarity to oxazolidinones. However,
they have rarely been employed as biologically active agents
and then only in racemic form.[3] Their absence in the
medicinal chemistry literature likely stems from the lack of
synthetic methodology for their preparation in enantiomer-
ically pure form and, consequently, the fact that it is unclear
whether they would be configurationally stable. In this
communication we document the convenient asymmetric
synthesis of a wide range of substituted 1,2,4-oxadiazolidi-
nones by cycloaddition. Access to the enantiomerically pure
compounds allows us to ascertain for the first time the
configurational stability of this class of compounds, including
that of the unsubstituted, previously unknown parent hetero-
cycle 3.
The cycloaddition of isocyanates and nitrones was first
reported by Goldschmidt and Beckmann in 1890, but it was
not until almost 100 years later (1987) that the structure of the
cycloadducts was firmly established as 1,2,4-oxadiazolidi-
nones.[4] In order to exploit these heterocycles as potentially
useful, versatile building blocks, two key criteria must be met:
[*] T. Ritter, Prof. Dr. E. M. Carreira
Laboratorium fꢀr Organische Chemie, ETH Hꢁnggerberg
8093 Zꢀrich (Switzerland)
Fax: (+41)1-632-1328
E-mail: carreira@org.chem.ethz.ch
[**] We thank the Swiss National Science Foundation and F. Hoffmann-
LaRoche AG for support of this research, the Fonds der Chemischen
Industrie for a Kekulꢂ Fellowship (T.R.), and Prof. Andrea Vasella for
helpful discussions.
The enantiomeric oxadiazolidinones can be accessed by
using the erythrose-derived auxiliary [Eq. (3)] and removing
the auxiliary from the heterocyclic product [Eq. (4)]. In
analogy to the cycloadditions described above, concentration
Supporting information for this article is available on the WWW
936
ꢀ 2005 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
DOI: 10.1002/anie.200461934
Angew. Chem. Int. Ed. 2005, 44, 936 –938